

## Board Composition Update

Genetic Signatures [ASX:GSS] (“GSS” or “the Company”), a global molecular diagnostics company is pleased to announce the appointment of Dr Jenny Harry to the Genetic Signatures Board as Non-Executive Director effective 1 October 2024.

Dr Harry has over 25 years’ experience in executive management of companies in the biotechnology, diagnostic and pharmaceutical sectors. She has a PhD in Developmental Biology from Macquarie University and is an accomplished CEO with experience in growing companies from start-up to commercialisation.

Dr Harry is currently a Non-Executive Director of Neuren Pharmaceuticals Limited (ASX: NEU) and Aeris Environmental Ltd (ASX: AEI) and is a member of the IP Committee of the Children’s Medical Research Institute.

Also, Mr Stephane Chatonsky who has provided meaningful contribution to the Board during a period of change at Genetic Signatures, has resigned to focus on his other commitments.

*“We are pleased that we have been able to attract someone of Dr Harry’s calibre to Genetic Signatures. This appointment adds deep scientific, commercialisation and industry experience to our Board to complement its existing skills as the Company moves to the next phase of growth following the recent FDA clearance of our EasyScreen™ Gastrointestinal Parasite Detection Kit in June of this year”* said Dr Nick Samaras, Chair of Genetic Signatures. *“I would also like to thank Mr Chatonsky for his contributions to the Company during his tenure.”*

For further information, see our website ([www.geneticsignatures.com](http://www.geneticsignatures.com)) or contact us as below:

**Mr Neil Gunn**  
Interim Chief Executive Officer  
[neil.gunn@geneticsignatures.com](mailto:neil.gunn@geneticsignatures.com)

**Karl Pechmann**  
Chief Financial Officer  
[karl.pechmann@geneticsignatures.com](mailto:karl.pechmann@geneticsignatures.com)

**About Genetic Signatures Limited:** Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures’ proprietary MDx 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its 3base® technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.